Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -146.9 Million SEK | -5.58% |
| 2022 | -120.1 Million SEK | -106.06% |
| 2021 | -58.28 Million SEK | 59.67% |
| 2020 | -144.5 Million SEK | -386.92% |
| 2019 | -29.67 Million SEK | 46.66% |
| 2018 | -55.64 Million SEK | 8.2% |
| 2017 | -60.61 Million SEK | -210.62% |
| 2016 | -19.51 Million SEK | 25.22% |
| 2015 | -26.09 Million SEK | 11.43% |
| 2014 | -29.45 Million SEK | -179.02% |
| 2013 | -10.55 Million SEK | 43.24% |
| 2012 | -18.6 Million SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 2666.00 SEK | -99.64% |
| 2009 | 732.55 Thousand SEK | 43.84% |
| 2008 | 509.27 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.8 Million SEK | 12.5% |
| 2024 Q1 | 9.6 Million SEK | 132.32% |
| 2023 FY | -126.8 Million SEK | -5.58% |
| 2023 Q2 | -36.9 Million SEK | 14.98% |
| 2023 Q1 | -43.4 Million SEK | 10.52% |
| 2023 Q3 | -41.7 Million SEK | -13.01% |
| 2023 Q4 | -29.7 Million SEK | 28.78% |
| 2022 Q1 | -14.57 Million SEK | 18.08% |
| 2022 FY | -120.1 Million SEK | -106.06% |
| 2022 Q4 | -48.5 Million SEK | -29.33% |
| 2022 Q3 | -37.5 Million SEK | -92.4% |
| 2022 Q2 | -19.49 Million SEK | -33.72% |
| 2021 Q2 | -22.79 Million SEK | -176.43% |
| 2021 Q3 | -9.45 Million SEK | 58.51% |
| 2021 Q4 | -17.79 Million SEK | -88.16% |
| 2021 Q1 | -8.24 Million SEK | 86.88% |
| 2021 FY | -58.28 Million SEK | 59.67% |
| 2020 Q2 | -26.7 Million SEK | 30.13% |
| 2020 FY | -144.5 Million SEK | -386.92% |
| 2020 Q4 | -62.86 Million SEK | -275.97% |
| 2020 Q1 | -38.22 Million SEK | -314.85% |
| 2020 Q3 | -16.72 Million SEK | 37.39% |
| 2019 Q1 | 28.66 Million SEK | 317.97% |
| 2019 FY | -29.67 Million SEK | 46.66% |
| 2019 Q2 | -21.66 Million SEK | -175.58% |
| 2019 Q3 | -27.46 Million SEK | -26.76% |
| 2019 Q4 | -9.21 Million SEK | 66.45% |
| 2018 Q3 | -11.27 Million SEK | 46.46% |
| 2018 Q4 | -13.15 Million SEK | -16.62% |
| 2018 FY | -55.64 Million SEK | 8.2% |
| 2018 Q1 | -10.15 Million SEK | 54.89% |
| 2018 Q2 | -21.06 Million SEK | -107.36% |
| 2017 FY | -60.61 Million SEK | -210.62% |
| 2017 Q4 | -22.51 Million SEK | -10.55% |
| 2017 Q3 | -20.36 Million SEK | -93.23% |
| 2017 Q2 | -10.54 Million SEK | -49.57% |
| 2017 Q1 | -7.04 Million SEK | -10.61% |
| 2016 Q1 | -1.91 Million SEK | 52.07% |
| 2016 FY | -19.51 Million SEK | 25.22% |
| 2016 Q4 | -6.37 Million SEK | -71.4% |
| 2016 Q3 | -3.71 Million SEK | 50.51% |
| 2016 Q2 | -7.51 Million SEK | -292.42% |
| 2015 Q3 | -7.55 Million SEK | -7.21% |
| 2015 FY | -26.09 Million SEK | 11.43% |
| 2015 Q1 | -7.5 Million SEK | 44.72% |
| 2015 Q2 | -7.04 Million SEK | 6.17% |
| 2015 Q4 | -3.99 Million SEK | 47.12% |
| 2014 Q2 | -7.33 Million SEK | -320.81% |
| 2014 Q1 | -1.74 Million SEK | 41.52% |
| 2014 Q4 | -13.57 Million SEK | -99.69% |
| 2014 Q3 | -6.79 Million SEK | 7.36% |
| 2014 FY | -29.45 Million SEK | -179.02% |
| 2013 Q2 | -1.91 Million SEK | 54.32% |
| 2013 FY | -10.55 Million SEK | 43.24% |
| 2013 Q4 | -2.98 Million SEK | -103.97% |
| 2013 Q3 | -1.46 Million SEK | 23.74% |
| 2013 Q1 | -4.19 Million SEK | 77.44% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | -18.6 Million SEK | 0.0% |
| 2012 Q4 | -18.6 Million SEK | -668.95% |
| 2012 Q3 | -2.41 Million SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2010 Q2 | 2666.00 SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | 2666.00 SEK | -99.64% |
| 2010 Q3 | - SEK | -100.0% |
| 2009 FY | 732.55 Thousand SEK | 43.84% |
| 2008 FY | 509.27 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 113.002% |
| Camurus AB (publ) | 1.58 Billion SEK | 109.294% |
| Mendus AB (publ) | 28.48 Million SEK | 615.674% |
| Lipum AB (publ) | 53 Thousand SEK | 277269.811% |
| NextCell Pharma AB | -43.74 Million SEK | -235.786% |
| Simris Alg AB (publ) | 2 Million SEK | 7419.382% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 1409.469% |
| Active Biotech AB (publ) | -1.67 Million SEK | -8670.149% |
| Amniotics AB (publ) | -1.93 Million SEK | -7511.399% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -34628.132% |
| BioArctic AB (publ) | 346.31 Million SEK | 142.418% |
| Cantargia AB (publ) | -3.45 Million SEK | -4156.737% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 8960.072% |
| CombiGene AB (publ) | -21.29 Million SEK | -589.973% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -4003.352% |
| Genovis AB (publ.) | 54 Million SEK | 372.032% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -979233.333% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -326.849% |
| Intervacc AB (publ) | -13.79 Million SEK | -964.956% |
| Kancera AB (publ) | -1.96 Million SEK | -7375.827% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 5333.345% |
| LIDDS AB (publ) | -12.92 Million SEK | -1036.821% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -2770.823% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 1574.455% |
| OncoZenge AB (publ) | 3000.00 SEK | 4896766.667% |
| Saniona AB (publ) | 11.78 Million SEK | 1346.923% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -4194.066% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 515.112% |
| Xintela AB (publ) | 78 Thousand SEK | 188433.333% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -1497.781% |
| Ziccum AB (publ) | -23.28 Million SEK | -530.851% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 8.579% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 451.545% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 6866.467% |
| Corline Biomedical AB | 28.38 Million SEK | 617.618% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | -19.69% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 647.705% |
| Aptahem AB (publ) | 2.63 Million SEK | 5684.175% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 190879.221% |
| Fluicell AB (publ) | 1.73 Million SEK | 8552.244% |
| Biovica International AB (publ) | 6.87 Million SEK | 2236.106% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -530.932% |
| AcouSort AB (publ) | 8.38 Million SEK | 1851.103% |
| Abliva AB (publ) | -35.66 Million SEK | -311.912% |
| 2cureX AB (publ) | -37.48 Million SEK | -291.869% |
| I-Tech AB | 27.56 Million SEK | 632.903% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 307.044% |
| Cyxone AB (publ) | 2.61 Million SEK | 5726.197% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 4416.779% |
| Biosergen AB | -456 Thousand SEK | -32114.912% |
| Nanologica AB (publ) | -76 Thousand SEK | -193189.474% |
| SynAct Pharma AB | -778 Thousand SEK | -18781.748% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -76013.99% |
| BioInvent International AB (publ) | 71.46 Million SEK | 305.567% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 839.157% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 504.694% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 10140.874% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -13903.813% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 4788.797% |